Biovica International
15.9.2021 08:21:46 CEST | ACCESS Newswire | Press release
UPPSALA, SE / ACCESSWIRE / September 15, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)
Biovica, active in cancer diagnostics, today announces that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer.
"SWOG researchers have demonstrated that a blood serum test can identify which of these patients have slow-growing disease that might be controlled with a simple aromatase inhibitor pill alone," said co-author of the paper, Dr. Lajos Pusztai, MD, PhD, Yale University Cancer Center.
"We are very proud to see the strong DiviTum®TKa results being published in Clinical Cancer Research. This highly reputable scientific journal by AACR focuses on innovative clinical and translational research bridging the laboratory and the clinic. The publication is a great recognition for DiviTumTKa and an important step to establishing the test as a standard tool for monitoring treatment of metastatic breast cancer to the benefit of patients and payers," said Anders Rylander, CEO of Biovica.
As previously announced, results demonstrate that patients with low TKa levels (using a predefined cut-off) before treatment initiation will do significantly better than patients expressing high levels of TKa. Progression free survival (PFS) was 17.3 vs 11.2 months and overall survival (OS) was 58 vs 30 months, respectively. In addition, similar results were observed during treatment, where patients with low TKa showed significantly longer PFS and OS. Furthermore, results support the potential clinical use of DiviTum®TKa to identify low-TKa patients as best suited for endocrine monotherapy, whereas those with elevated TKa values appear to benefit from combination therapies.
The analysis measured thymidine kinase activity (TKa) levels in 1,726 serum samples from more than 400 patients in SWOG S0226 and is the largest study to evaluate DiviTum®TKa for prognostic and serial monitoring of metastatic breast cancer. The study constitutes the foundation for the clinical validation of DiviTum®TKa in Biovica's 510(k)-application to the FDA. DiviTum®TKa is 510(k) pending. Not available for sale in the United States.
Link to study: Clinical Cancer Research
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/664165/DiviTumRTKa-Results-from-SWOG-Study-Published-in-Clinical-Cancer-Research
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
LiberNovo 2026 Triple Launch: SE, Pro, and Maxis Introduce Dynamic Ergonomics for Every Body Type Across Europe18.5.2026 19:00:00 CEST | Press release
LONDON, GB / ACCESS Newswire / May 18, 2026 / LiberNovo, the premium ergonomic chair brand pioneering movement-based seating, today confirmed the full details of its 2026 product expansion for the European market. Three new lines-the Omni SE, Omni Pro, and the all-new Maxis series-will be available to customers across the UK and EU starting June 16, with pre-orders now open. Across Europe, the shift toward hybrid and remote work has turned the home office into a permanent fixture. Yet the chair at the centre of that setup is often the last thing to be upgraded. Most ergonomic seating still operates on a decades-old premise: find the correct posture, lock it in, stay put. LiberNovo rejects that model entirely. Its Dynamic Ergonomics platform is built around continuous adaptation-chairs that respond to how users actually move through their day, rather than forcing them into a fixed position. With three distinct product lines, that approach now reaches users of every build and budget. Omn
Europe's Healthcare IT Market Enters the 2027 Readiness Cycle as Black Book Names 26 Top Client-Rated Vendors During HIMSS26 Week in Copenhagen18.5.2026 18:00:00 CEST | Press release
Category-specific honors identify client-rated leaders in data-ready EHRs, interoperability, enterprise imaging, cloud, cybersecurity, AI, advisory, analytics, clinical decision support and digital health infrastructure COPENHAGEN, DK / ACCESS Newswire / May 18, 2026 / Black Book Research today announced its 2026 European Healthcare IT Client Satisfaction Honors, recognizing 26 healthcare technology vendors and platforms whose strongest client-facing performance aligns with the next phase of European digital health: trusted data, cross-border interoperability, AI accountability, cybersecurity resilience, cloud modernization, enterprise imaging liquidity, analytics readiness and clinical workflow transformation. The announcement is timed to HIMSS26 Europe, taking place 19-21 May 2026 at the Bella Center in Copenhagen, Denmark, where healthcare leaders, innovators and policymakers are convening around digital maturity, AI, interoperability, cybersecurity and health system transformation.
Tyson Fury, The Gypsy King, Joins Datavault AI as International Spokesperson to Champion Athlete Data Monetization18.5.2026 14:37:00 CEST | Press release
Forbes' Third Highest-Paid Athlete in the World Brings Global Platform to Datavault AI's Sports Illustrated Exchange and NIL Monetization Initiative PHILADELPHIA, PA / ACCESS Newswire / May 18, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset (‘RWA') tokenization technologies, today announced that two-time world heavyweight champion Tyson Fury has signed on as International Spokesperson for Datavault AI a deal brokered by Nick Hunter of P11. Ranked No. 3 on Forbes' 2025 list of the world's highest-paid athletes with $146 million in estimated earnings (Forbes 2025), Fury brings global star power, and a uniquely personal understanding of what it means to own, protect, and capitalize on a name, to Datavault AI's mission of empowering individuals and organizations to monetize their data and digital assets. Known worldwide as "The Gypsy King," his appointment immediately precede
Tabor Redefines Anti-Drone Testing with Software-Defined SDR Platform15.5.2026 22:55:00 CEST | Press release
NESHER, ISRAEL / ACCESS Newswire / May 15, 2026 / Tabor Electronics today announced the commercial release of its Anti-Drone Test and Evaluation (T&E) solution, introducing a software-defined approach to validating counter-unmanned aircraft systems (C-UAS). Built on the company's Proteus™ Software Defined Radio (SDR) platform, the solution enables defense and security organizations to test and deploy counter-drone technologies in rapidly changing threat environments. As low-cost drones proliferate and communication protocols evolve, traditional hardware-bound test environments are struggling to keep pace. Tabor's platform replaces these constraints with a programmable framework that allows engineering teams to emulate and validate real-world RF scenarios in controlled lab environments-reducing reliance on extended field testing while accelerating development timelines. Originally developed in collaboration with leading anti-drone technology companies, the solution has already been prov
Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program14.5.2026 21:05:00 CEST | Press release
Highlights: WellCare Today brings established RPM, RTM and CCM infrastructure with wearable technology integrations and connected monitoring solutions Combination expected to integrate Wellgistics Health recently announced MSO initiative with Kare Clinicals and its network of 6,500+ independent pharmacies Proposed platform designed to enhance patient engagement, medication adherence, remote monitoring and longitudinal care coordination Proposed transaction valued at approximately $15 million Strategic initiative intended to create additional clinical revenue opportunities for participating pharmacies and providers TAMPA, FL / ACCESS Newswire / May 14, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it has executed a non-binding letter of intent ("LOI") to acquire WellCare Today. The proposed transaction structure includes a structured cash payment of $3 million,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom